Sobre este episodio
Pedro Magno e Lucca Cirillo conversam sobre os alvos de LDL em 4 populações:- Evento cardiovascular prévio- Presença de diabetes- LDL > 190 mg/dL- Outras situações Veja mais em https://www.tadeclinicagem.com.br/guia/259/hipercolesterolemia-familiar/Veja o vale a pena ouvir de novo em https://www.youtube.com/watch?v=k42rmssU1xE&ab_channel=TadeClinicagemReferências:1. Mach, François et al. “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.” European heart journal vol. 41,1 (2020): 111-188. doi:10.1093/eurheartj/ehz4552. Faludi, André Arpad et al. “Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017.” Arquivos brasileiros de cardiologia vol. 109,2 Supl 1 (2017): 1-76. doi:10.5935/abc.201701213. Grundy, Scott M et al. “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Journal of the American College of Cardiology vol. 73,24 (2019): 3168-3209. doi:10.1016/j.jacc.2018.11.0024. Pearson, Glen J et al. “2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.” The Canadian journal of cardiology vol. 37,8 (2021): 1129-1150. doi:10.1016/j.cjca.2021.03.0165. Marx, Nikolaus et al. “2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.” European heart journal vol. 44,39 (2023): 4043-4140. doi:10.1093/eurheartj/ehad1926. Vrints, Christiaan et al. “2024 ESC Guidelines for the management of chronic coronary syndromes.” European heart journal vol. 45,36 (2024): 3415-3537. doi:10.1093/eurheartj/ehae1777. Hong, Sung-Jin et al. “Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.” JAMA vol. 329,13 (2023): 1078-1087. doi:10.1001/jama.2023.24878. Cannon, Christopher P et al. “Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.” The New England journal of medicine vol. 372,25 (2015): 2387-97. doi:10.1056/NEJMoa14104899. Sabatine, Marc S et al. “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.” The New England journal of medicine vol. 376,18 (2017): 1713-1722. doi:10.1056/NEJMoa161566410. http://departamentos.cardiol.br/sbc-da/2015/calculadoraer2017/etapa1.html11. Lipidology update: targets and timing of well-established therapies, Luigina Guasti 1, MD, PhD, FAHA, FESC; Alessandro Lupi 2, MD at https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopractice/lipidology-update-targets-and-timing-of-well-established-therapies12. Ray, Kausik K et al. “EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.” European journal of preventive cardiology vol. 28,11 (2021): 1279-1289. doi:10.1093/eurjpc/zwaa04713. Cholesterol Treatment Trialists’ (CTT) Collaboration et al. “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.” Lancet (London, England) vol. 376,9753 (2010): 1670-81. doi:10.1016/S0140-6736(10)61350-5
